



## Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

June 3, 2025

VANCOUVER, British Columbia and BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Conference taking place in Miami, FL, from June 9-11, 2025.

Fireside Chat Presentation Details:

**Date:** Tuesday, June 10, 2025

**Time:** 3:20-3:55 PM Eastern Time

**Webcast:** [Register here](#)

**Presenter:** Ian Mortimer, President and Chief Executive Officer

A live audio webcast of the company presentation will be available on the "[Investors](#)" section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.

### About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit [www.xenon-pharma.com](http://www.xenon-pharma.com).

"Xenon" and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

#### Contacts:

*For Investors:*

Chad Fugere

Vice President, Investor Relations

(857) 675-7275

[investors@xenon-pharma.com](mailto:investors@xenon-pharma.com)

*For Media:*

Colleen Alabiso

Senior Vice President, Corporate Affairs

(617) 671-9238

[media@xenon-pharma.com](mailto:media@xenon-pharma.com)



Source: Xenon Pharmaceuticals Inc.